An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Corticotropin (Primary)
- Indications Scleritis
- Focus Therapeutic Use
- Acronyms ATLAS
- 04 Mar 2019 Planned End Date changed from 31 Dec 2019 to 1 Jun 2020.
- 04 Mar 2019 Planned primary completion date changed from 30 Sep 2019 to 1 Jun 2020.
- 04 Mar 2019 Status changed from not yet recruiting to recruiting.